|1||NCT02978625||Recruiting||Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers||
||68||All||18 Years and older (Adult, Senior)||NCT02978625||NCI-2016-01804
|September 18, 2017||January 31, 2019||January 31, 2019||December 1, 2016||December 19, 2017||
|2||NCT01366144||Recruiting||Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction||
||NIH / Industry||
||276||All||18 Years and older (Adult, Senior)||NCT01366144||NCI-2011-02500
|June 20, 2011||July 31, 2017||June 3, 2011||July 26, 2017||
† Study has passed its completion date and status has not been verified in more than two years.